INR 789.4
(0.41%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.8 Billion INR | -13.11% |
2022 | 2.07 Billion INR | -22.04% |
2021 | 2.65 Billion INR | -8.67% |
2020 | 2.91 Billion INR | -18.44% |
2019 | 3.56 Billion INR | 59.87% |
2018 | 2.23 Billion INR | -40.76% |
2017 | 3.76 Billion INR | 63.65% |
2016 | 2.3 Billion INR | -3.63% |
2015 | 2.38 Billion INR | 16.2% |
2014 | 2.05 Billion INR | -14.58% |
2013 | 2.4 Billion INR | -0.08% |
2012 | 2.4 Billion INR | 11.65% |
2011 | 2.15 Billion INR | 13.46% |
2010 | 1.9 Billion INR | 13.84% |
2009 | 1.67 Billion INR | 8.09% |
2008 | 1.54 Billion INR | 15.4% |
2007 | 1.33 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.61 Billion INR | 0.0% |
2024 Q1 | - INR | -100.0% |
2023 Q1 | - INR | -100.0% |
2023 Q2 | 1.68 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 1.8 Billion INR | 0.0% |
2023 FY | 1.8 Billion INR | -13.11% |
2022 Q2 | 2.59 Billion INR | 0.0% |
2022 FY | 2.07 Billion INR | -22.04% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 2.07 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2021 Q4 | 2.65 Billion INR | 0.0% |
2021 Q2 | 2.66 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 2.65 Billion INR | -8.67% |
2021 Q3 | - INR | -100.0% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 FY | 2.91 Billion INR | -18.44% |
2020 Q2 | 3.2 Billion INR | 0.0% |
2020 Q4 | 2.91 Billion INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 FY | 3.56 Billion INR | 59.87% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 3.69 Billion INR | 0.0% |
2019 Q4 | 3.56 Billion INR | 0.0% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 2.89 Billion INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 FY | 2.23 Billion INR | -40.76% |
2018 Q4 | 2.23 Billion INR | 0.0% |
2017 Q4 | 3.76 Billion INR | 0.0% |
2017 Q3 | - INR | -100.0% |
2017 FY | 3.76 Billion INR | 63.65% |
2017 Q1 | - INR | -100.0% |
2017 Q2 | 2.62 Billion INR | 0.0% |
2016 Q1 | - INR | -100.0% |
2016 Q4 | 2.3 Billion INR | 0.0% |
2016 Q2 | 2.38 Billion INR | 0.0% |
2016 FY | 2.3 Billion INR | -3.63% |
2016 Q3 | - INR | -100.0% |
2015 Q4 | 2.38 Billion INR | 0.0% |
2015 FY | 2.38 Billion INR | 16.2% |
2015 Q3 | - INR | -100.0% |
2015 Q2 | 2.23 Billion INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2014 Q1 | - INR | -100.0% |
2014 FY | 2.05 Billion INR | -14.58% |
2014 Q4 | 2.05 Billion INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 Q2 | 2.17 Billion INR | 0.0% |
2013 Q2 | 1.88 Billion INR | 0.0% |
2013 Q4 | 2.4 Billion INR | 0.0% |
2013 FY | 2.4 Billion INR | -0.08% |
2013 Q3 | - INR | -100.0% |
2013 Q1 | - INR | -100.0% |
2012 FY | 2.4 Billion INR | 11.65% |
2012 Q4 | 2.4 Billion INR | 0.0% |
2012 Q2 | 1.58 Billion INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2011 Q4 | 2.15 Billion INR | 0.0% |
2011 FY | 2.15 Billion INR | 13.46% |
2010 FY | 1.9 Billion INR | 13.84% |
2009 FY | 1.67 Billion INR | 8.09% |
2008 FY | 1.54 Billion INR | 15.4% |
2007 FY | 1.33 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 88.933% |
Aurobindo Pharma Limited | 152.2 Billion INR | 98.817% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 65.236% |
Granules India Limited | 22.95 Billion INR | 92.154% |
Indoco Remedies Limited | 10.34 Billion INR | 82.585% |
Achyut Healthcare Limited | 2.01 Million INR | -89373.423% |
Ajanta Pharma Limited | 10.71 Billion INR | 83.183% |
Alkem Laboratories Limited | 48.6 Billion INR | 96.294% |
Alpa Laboratories Limited | 307.12 Million INR | -486.444% |
Brooks Laboratories Limited | 248.6 Million INR | -624.494% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 50.805% |
Bajaj HealthCare Limited | 4.86 Billion INR | 62.999% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 14.593% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.316% |
Eris Lifesciences Limited | 38.26 Billion INR | 95.293% |
FDC Limited | 3.7 Billion INR | 51.442% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.234% |
Gufic Biosciences Limited | 5.59 Billion INR | 67.836% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 21.331% |
Ipca Laboratories Limited | 33.74 Billion INR | 94.662% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -506.921% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 39.437% |
Lasa Supergenerics Limited | 541.92 Million INR | -232.352% |
Laurus Labs Limited | 42.71 Billion INR | 95.783% |
Lupin Limited | 96.23 Billion INR | 98.128% |
Mankind Pharma Limited | 23.87 Billion INR | 92.456% |
Medicamen Biotech Limited | 940.36 Million INR | -91.532% |
Medico Remedies Limited | 438.24 Million INR | -310.981% |
Megasoft Limited | 1.85 Billion INR | 2.808% |
NATCO Pharma Limited | 10.53 Billion INR | 82.899% |
Piramal Pharma Limited | 74 Billion INR | 97.566% |
RPG Life Sciences Limited | 1.38 Billion INR | -30.496% |
Sigachi Industries Limited | 2.53 Billion INR | 28.846% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.019% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 11.46% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -54.573% |
Unichem Laboratories Limited | 8.06 Billion INR | 77.679% |
Wanbury Limited | 3.15 Billion INR | 42.922% |
Windlas Biotech Limited | 1.76 Billion INR | -2.178% |
ZIM Laboratories Limited | 2.08 Billion INR | 13.44% |
Zydus Lifesciences Limited | 71.79 Billion INR | 97.491% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 53.734% |
Divi's Laboratories Limited | 18.99 Billion INR | 90.516% |
Hester Biosciences Limited | 3.59 Billion INR | 49.896% |
Procter & Gamble Health Limited | 2.56 Billion INR | 29.677% |
Amrutanjan Health Care Limited | 783.82 Million INR | -129.784% |
Bal Pharma Limited | 2.51 Billion INR | 28.279% |
Strides Pharma Science Limited | 37.68 Billion INR | 95.22% |
Venus Remedies Limited | 1.39 Billion INR | -29.315% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 78.17% |
Nectar Lifesciences Limited | 11.21 Billion INR | 83.945% |
Shilpa Medicare Limited | 12.93 Billion INR | 86.073% |
Aarti Drugs Limited | 11.5 Billion INR | 84.344% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 71.542% |
Suven Life Sciences Limited | 148.62 Million INR | -1111.874% |
Ind-Swift Limited | 13.45 Billion INR | 86.612% |
Valiant Laboratories Limited | 1.05 Billion INR | -70.195% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 83.18% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 87.266% |
Themis Medicare Limited | 1.88 Billion INR | 4.578% |
Hikal Limited | 12.99 Billion INR | 86.14% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.805% |
Sequent Scientific Limited | 8.27 Billion INR | 78.232% |
Wockhardt Limited | 39.87 Billion INR | 95.483% |
Jubilant Pharmova Limited | 61.27 Billion INR | 97.061% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -523.652% |
Neuland Laboratories Limited | 5.49 Billion INR | 67.244% |
Morepen Laboratories Limited | 4.45 Billion INR | 59.615% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -179.725% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 8.866% |